Sitravatinib malate is under clinical development by Mirati Therapeutics and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Metastatic Renal Cell Carcinoma have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sitravatinib malate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sitravatinib malate overview
Sitravatinib malate is under development for the treatment of renal cell carcinoma, gallbladder cancer, advanced biliary tract cancer, oral cavity cancer, metastatic urothelial tract cancer (bladder cancer), gastroesophageal junction carcinoma, metastatic triple negative breast cancer, non-small cell lung cancer, metastatic hepatocellular carcinoma, renal cell carcinoma, epithelial ovarian carcinoma, liposarcoma, well-differentiated or de-differentiated liposarcoma, soft tissue sarcomas, peripheral nerve sheath Tumor (neurofibrosarcoma), synovial sarcoma, rhabdomyosarcoma, endometrial cancer, esophageal squamous cell carcinoma, metastatic uveal melanoma and metastatic melanoma. The drug candidate is administered orally. It is a second generation multi-targeted kinase inhibitor. It inhibits RET, TRK, DDR and EphRs as well as Met, Axl and VEGFRs (VEGFR 1, 2 3), c-Met, PDGFR and KIT. It was under development for squamous cell carcinoma of head and neck, metastatic castrate-resistant prostate cancer with bone metastasis, thymoma and squamous non-small cell lung cancer.
Mirati Therapeutics overview
Mirati Therapeutics is a clinical-stage oncology company that developing novel therapeutics to address the genetic and immunological promoters of cancer. The company product pipeline includes Adagrasib (MRTX849), an oral small molecule inhibitor of KRASG12C and MRTX1133, a potent small molecule inhibitor of the KRASG12D for the treatment of colorectal and pancreatic cancer. Mirati Therapeutics is also evaluating Sitravatinib, a multi kinase inhibitor against non-small cells lung cancer in non-smokers and MRTX1719 to treat MTAP deleted cancers. The company has partner with Zai Lab, Beigene, Sanofi, Boehringer, Novartis and Bristol Myers Squibb, among others. It operates in Canada, Netherlands and the US. Mirati Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of Sitravatinib malate’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
